Last reviewed · How we verify
Monovalent HBV vaccine
At a glance
| Generic name | Monovalent HBV vaccine |
|---|---|
| Also known as | Engerix-B |
| Sponsor | University of North Carolina, Chapel Hill |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The COMBAT HBV Feasibility Trial (PHASE4)
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- Neovac 2 Burkina Faso: Impact of the Integration of Hepatitis B Birth Dose Vaccine Into the Infant Immunization Schedule (NA)
- Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults (PHASE1)
- Arresting Vertical Transmission of Hepatitis B Virus (PHASE4)
- Immunogenicity of the Hepatitis B Vaccine (PHASE4)
- Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc (PHASE4)
- Evaluation of Antibody Persistence & Immune Memory in Subjects Vaccinated During Adolescence With Twinrix™ (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Monovalent HBV vaccine CI brief — competitive landscape report
- Monovalent HBV vaccine updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI